Canaccord Genuity Maintains a 'Hold' on ResMed (RMD); Raising PT on Solid Q3
Tweet
Share
E-mailGet Alerts RMD Hot Sheet
Price: $183.78 --0%
Rating Summary:
13 Buy, 9 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 11 | New: 6
Rating Summary:
13 Buy, 9 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 11 | New: 6
Join SI Premium – FREE
Canaccord Genuity maintains a 'Hold' on ResMed (NYSE: RMD) price target raised to $32.00.
Analyst, Jason R. Mills, said, "RMD delivered strong revenue and earnings in F3Q, driven in large part by strong US sales versus easy Y/Y comparisons, solid GM, lower tax rate and share buyback. Operating income growth – which had been negative over the past 3 quarters – rebounded (+22%). With easy comps over the next few quarters, we expect OI growth to stay around these levels near term. New products in both masks and flow generators (namely in the US), coupled with positive mix shift in flow generators to APAP and Bi-level, should help RMD maintain double-digit revenue growth in the US. However, OUS growth – facing difficult comps and sluggish economic conditions - grew 4% and may continue to under-perform, in our view. We model operating income growth improving to 12% in F13E from 9% in F12E. We model 11% EPS growth in F13E, with variance largely depending on further tax rate reductions and/or share repurchases, in our estimation."
For an analyst ratings summary and ratings history on ResMed click here. For more ratings news on ResMed click here.
Shares of ResMed closed at $32.05 yesterday.
Analyst, Jason R. Mills, said, "RMD delivered strong revenue and earnings in F3Q, driven in large part by strong US sales versus easy Y/Y comparisons, solid GM, lower tax rate and share buyback. Operating income growth – which had been negative over the past 3 quarters – rebounded (+22%). With easy comps over the next few quarters, we expect OI growth to stay around these levels near term. New products in both masks and flow generators (namely in the US), coupled with positive mix shift in flow generators to APAP and Bi-level, should help RMD maintain double-digit revenue growth in the US. However, OUS growth – facing difficult comps and sluggish economic conditions - grew 4% and may continue to under-perform, in our view. We model operating income growth improving to 12% in F13E from 9% in F12E. We model 11% EPS growth in F13E, with variance largely depending on further tax rate reductions and/or share repurchases, in our estimation."
For an analyst ratings summary and ratings history on ResMed click here. For more ratings news on ResMed click here.
Shares of ResMed closed at $32.05 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Intermediate Capital Group (ICP:LN) (ICGUF) PT Raised to GBP22.50 at Citi
- Lam Research (LRCX) PT Raised to $1,130 at B.Riley
- Heineken NV (HEIA:NA) (HEINY) PT Raised to EUR77 at RBC Capital
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Analyst PT ChangeRelated Entities
Stock Buyback, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
